[go: up one dir, main page]

UA85686C2 - Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}- 1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение как лекарственного средства, способ его получения - Google Patents

Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}- 1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение как лекарственного средства, способ его получения

Info

Publication number
UA85686C2
UA85686C2 UAA200603253A UAA200603253A UA85686C2 UA 85686 C2 UA85686 C2 UA 85686C2 UA A200603253 A UAA200603253 A UA A200603253A UA A200603253 A UAA200603253 A UA A200603253A UA 85686 C2 UA85686 C2 UA 85686C2
Authority
UA
Ukraine
Prior art keywords
methyl
carbonyl
medicament
enylaminomethyl
hexyloxycarbonylamidino
Prior art date
Application number
UAA200603253A
Other languages
English (en)
Ukrainian (uk)
Inventor
Райнер Зоботта
Петер Зігер
Рольф Шмід
Original Assignee
Бьорінгер Інгельхайм Інтернаціональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34202202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA85686(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бьорінгер Інгельхайм Інтернаціональ Гмбх filed Critical Бьорінгер Інгельхайм Інтернаціональ Гмбх
Publication of UA85686C2 publication Critical patent/UA85686C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Заявка касается метансульфоната этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1H-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты в кристаллических модификациях І и II, а также в виде полугидрата и применение этого соединения как лекарственного средства.
UAA200603253A 2003-08-29 2004-08-24 Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}- 1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение как лекарственного средства, способ его получения UA85686C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10339862A DE10339862A1 (de) 2003-08-29 2003-08-29 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
UA85686C2 true UA85686C2 (ru) 2009-02-25

Family

ID=34202202

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200603253A UA85686C2 (ru) 2003-08-29 2004-08-24 Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}- 1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение как лекарственного средства, способ его получения

Country Status (35)

Country Link
US (2) US20050234104A1 (ru)
EP (2) EP2060569B1 (ru)
JP (2) JP5348842B2 (ru)
KR (1) KR101331039B1 (ru)
CN (2) CN1845917B (ru)
AR (2) AR045520A1 (ru)
AT (2) ATE529420T1 (ru)
AU (2) AU2004274139B2 (ru)
BR (1) BRPI0413849A (ru)
CA (2) CA2537054C (ru)
CO (1) CO5660265A2 (ru)
CY (2) CY1109299T1 (ru)
DE (2) DE10339862A1 (ru)
DK (2) DK1660482T3 (ru)
EA (1) EA009736B1 (ru)
EC (2) ECSP066399A (ru)
ES (2) ES2326654T3 (ru)
HR (2) HRP20090311T1 (ru)
IL (1) IL173885A (ru)
ME (1) ME00340B (ru)
MX (1) MXPA06001959A (ru)
MY (2) MY145696A (ru)
NO (2) NO334115B1 (ru)
NZ (2) NZ545984A (ru)
PE (1) PE20050348A1 (ru)
PL (2) PL1660482T3 (ru)
PT (2) PT1660482E (ru)
RS (2) RS20060136A (ru)
SG (1) SG145734A1 (ru)
SI (2) SI2060569T1 (ru)
TW (2) TWI418553B (ru)
UA (1) UA85686C2 (ru)
UY (2) UY28493A1 (ru)
WO (1) WO2005028468A1 (ru)
ZA (1) ZA200600518B (ru)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE102005020002A1 (de) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) * 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102006054005A1 (de) * 2006-11-16 2008-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
MX2010010647A (es) * 2008-03-28 2010-10-20 Boehringer Ingelheim Int Proceso para preparar formulaciones de dabigatran para administracion oral.
AU2009272796A1 (en) * 2008-07-14 2010-01-21 Boehringer Ingelheim International Gmbh Method for manufacturing medicinal compounds containing dabigatran
EP2328581A1 (en) * 2008-08-19 2011-06-08 Boehringer Ingelheim International GmbH Use of dabigatranetexilate for treating patients with pulmonary hypertension
PE20110431A1 (es) 2008-11-11 2011-07-13 Boehringer Ingelheim Int Etexilato de dabigatran o una sal del mismo
WO2010130757A1 (en) 2009-05-14 2010-11-18 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
HUP1000069A2 (en) 2010-02-02 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag New salts for the preparation of pharmaceutical composition
US20130052262A1 (en) * 2010-03-01 2013-02-28 Sandra Brueck Dabigatran etexilate-containing oral pharmaceutical composition
JP2013521318A (ja) 2010-03-08 2013-06-10 ラティオファルム ゲー・エム・ベー・ハー ダビガトランエテキシラートを含有する医薬組成物
PL2588090T3 (pl) 2010-07-01 2017-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Doustne farmaceutyczne postacie dawkowania zawierające eteksylan dabigatranu i jego farmaceutycznie dopuszczalne sole
WO2012027543A1 (en) 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
ES2550771T3 (es) 2010-09-27 2015-11-12 Ratiopharm Gmbh Sal de bismesilato etexilato de dabigatrán, formas en estado sólido y proceso para la preparación de las mismas
US9006448B2 (en) 2010-12-06 2015-04-14 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and its salts
HUP1100244A2 (hu) 2011-05-11 2012-11-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Gyógyszeripari intermedierek és eljárás elõállításukra
WO2012162492A1 (en) 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
BR112014014795A2 (pt) 2011-12-22 2017-06-13 Boehringer Ingelheim Int sistema de pélete de multiunidade de liberação imediata
WO2013111163A2 (en) 2012-01-20 2013-08-01 Cadila Healthcare Limited Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
EP2806858A1 (en) 2012-01-24 2014-12-03 Boehringer Ingelheim International Gmbh Novel orally administered dabigatran formulation
JP6215239B2 (ja) 2012-02-21 2017-10-18 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ダビガトランエテキシラートの経口医薬組成物
EP2631234A1 (en) * 2012-02-23 2013-08-28 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013144971A1 (en) 2012-03-27 2013-10-03 Cadila Healthcare Limited New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
US9273030B2 (en) 2012-04-02 2016-03-01 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and salts thereof
US9365544B2 (en) * 2012-07-16 2016-06-14 Interquim, S.A. Process for the preparation of intermediates for the synthesis of Dabigatran Etexilate, and crystalline forms of said intermediates
IN2015DN01414A (ru) 2012-08-31 2015-07-03 Ranbaxy Lab Ltd
CN103664882A (zh) * 2012-09-20 2014-03-26 天津药物研究院 结晶变体形态的达比加群酯及其制备方法和用途
CN103864756B (zh) * 2012-12-11 2018-06-15 四川海思科制药有限公司 丁二磺酸达比加群酯及其制备方法和用途
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
CN104418840A (zh) * 2013-09-05 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯无水化合物
IN2014MU00675A (ru) 2014-02-26 2015-10-23 Megafine Pharma P Ltd
CN104892574A (zh) * 2014-03-04 2015-09-09 浙江海正药业股份有限公司 达比加群酯甲磺酸盐的晶型及其制备方法和用途
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
CN104974137A (zh) * 2014-04-04 2015-10-14 江苏天士力帝益药业有限公司 达比加群酯甲磺酸盐新晶型及其制备方法
CN105461686A (zh) * 2014-08-25 2016-04-06 江苏豪森药业股份有限公司 制备高纯度甲磺酸达比加群酯晶型的方法
CN104825422B (zh) * 2014-09-29 2017-12-12 普济生物科技（台州）有限公司 含达比加群酯甲磺酸盐的药物组合物及其制备方法
EP4205743A1 (en) 2014-12-31 2023-07-05 Shenzhen Pharmacin Co., Ltd. Pharmaceutical composition and preparation method therefor
CN104725360A (zh) * 2015-04-09 2015-06-24 重庆东得医药科技有限公司 一种甲磺酸达比加群酯ⅰ晶型的制备方法
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN107778291A (zh) * 2016-08-31 2018-03-09 亚宝药业集团股份有限公司 一种甲磺酸达比加群酯晶型ⅱ的制备方法
US12209141B2 (en) 2018-10-29 2025-01-28 Shanghai Synergy Pharmaceutical Sciences, Ltd. Dipeptide compounds and uses thereof
JP2020193184A (ja) * 2019-05-30 2020-12-03 ダイト株式会社 ダビガトランエテキシラートメタンスルホン酸塩の形態ｉの製造方法
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
CN114380793B (zh) * 2020-10-20 2024-02-23 北京澳合药物研究院有限公司 一种甲磺酸达比加群酯晶型i的制备方法及其应用
US11446286B1 (en) * 2022-02-28 2022-09-20 King Faisal University Treatment of fungal infections using dabigatran etexilate

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US4427468A (en) * 1976-01-16 1984-01-24 Her Majesty The Queen In Right Of Canada Curable propellant binding systems with bonding agent combination
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd 医薬組成物
US4675405A (en) 1984-09-21 1987-06-23 American Home Products Corporation Quinoline compounds as antiallergic and antithrombotic agents
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5416099A (en) 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
CA2141582C (en) 1992-08-05 2003-09-30 Angelo Mario Morella Pelletised pharmaceutical composition
JPH06340619A (ja) 1993-05-03 1994-12-13 Bristol Myers Squibb Co グアニジニルまたはアミジニル置換メチルアミノ複素環トロンビン抑制剤
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
DE19752843C2 (de) 1997-11-28 2003-01-09 Byk Gulden Lomberg Chem Fab Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol
DE10133786A1 (de) 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
NZ535663A (en) * 2002-03-07 2006-06-30 Boehringer Ingelheim Pharma Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester and the salts thereof
DE10245624A1 (de) * 2002-09-30 2004-04-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze
DE10209982A1 (de) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
DE10235639A1 (de) 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
JP2006524203A (ja) 2003-04-24 2006-10-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トロンビンの過剰形成及び／又はトロンビンレセプターの発現上昇により生じる血栓塞栓性疾病及び疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
US20050107438A1 (en) 2003-09-03 2005-05-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore
EP1609784A1 (de) 2004-06-25 2005-12-28 Boehringer Ingelheim Pharma GmbH & Co.KG Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen
US20060222640A1 (en) 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005020002A1 (de) 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102005061623A1 (de) 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
DE102005061624A1 (de) 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen

Also Published As

Publication number Publication date
CY1109299T1 (el) 2014-07-02
NZ545984A (en) 2009-08-28
SI1660482T1 (sl) 2009-10-31
CO5660265A2 (es) 2006-07-31
CN102167695B (zh) 2013-06-19
US20050234104A1 (en) 2005-10-20
DE502004009431D1 (en) 2009-06-10
HK1157760A1 (en) 2012-07-06
AU2010201457A1 (en) 2010-05-06
EP2060569A1 (de) 2009-05-20
CN102167695A (zh) 2011-08-31
AR073225A2 (es) 2010-10-20
CN1845917A (zh) 2006-10-11
ECSP066399A (es) 2006-09-18
JP5566332B2 (ja) 2014-08-06
MEP50608A (en) 2011-02-10
RS20060136A (sr) 2008-06-05
ZA200600518B (en) 2006-12-27
CY1112222T1 (el) 2015-12-09
RS53370B (sr) 2014-10-31
JP5348842B2 (ja) 2013-11-20
DK2060569T3 (da) 2012-01-23
MY145632A (en) 2012-03-15
AR045520A1 (es) 2005-11-02
JP2007504106A (ja) 2007-03-01
EP1660482B1 (de) 2009-04-29
JP2011178803A (ja) 2011-09-15
DE10339862A1 (de) 2005-03-24
ATE529420T1 (de) 2011-11-15
AU2010201457B2 (en) 2012-05-10
IL173885A (en) 2015-04-30
WO2005028468A1 (de) 2005-03-31
TWI418553B (zh) 2013-12-11
HK1096682A1 (en) 2007-06-08
ES2375896T3 (es) 2012-03-07
EA200600381A1 (ru) 2006-08-25
CA2749579C (en) 2013-04-16
ATE430145T1 (de) 2009-05-15
SG145734A1 (en) 2008-09-29
NZ578586A (en) 2011-01-28
CN1845917B (zh) 2011-05-11
UY28493A1 (es) 2005-03-31
AU2004274139B2 (en) 2010-05-13
ECSP11006399A (es) 2011-12-30
EP2060569B1 (de) 2011-10-19
KR20070031830A (ko) 2007-03-20
BRPI0413849A (pt) 2006-10-24
SI2060569T1 (sl) 2012-01-31
MY145696A (en) 2012-03-30
CA2537054C (en) 2011-12-06
NO334115B1 (no) 2013-12-16
PT2060569E (pt) 2011-12-29
PE20050348A1 (es) 2005-06-15
EP1660482A1 (de) 2006-05-31
ES2326654T3 (es) 2009-10-16
PT1660482E (pt) 2009-06-04
EA009736B1 (ru) 2008-02-28
HRP20090311T1 (en) 2009-07-31
CA2749579A1 (en) 2005-03-31
IL173885A0 (en) 2006-07-05
TW201202217A (en) 2012-01-16
PL1660482T3 (pl) 2009-08-31
UY32342A (es) 2011-07-29
US20080119523A1 (en) 2008-05-22
NO20130778L (no) 2006-03-28
ME00340B (me) 2011-05-10
AU2004274139A1 (en) 2005-03-31
US7932273B2 (en) 2011-04-26
TWI375674B (en) 2012-11-01
MXPA06001959A (es) 2006-05-17
DK1660482T3 (da) 2009-08-24
CA2537054A1 (en) 2005-03-31
KR101331039B1 (ko) 2013-11-20
PL2060569T3 (pl) 2012-03-30
TW200512206A (en) 2005-04-01
HRP20120028T1 (hr) 2012-01-31
NO20061420L (no) 2006-03-28

Similar Documents

Publication Publication Date Title
UA85686C2 (ru) Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}- 1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение как лекарственного средства, способ его получения
CY1108218T1 (el) Δισκιο που περιεχει 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλο}-1 -μεθυλο-1 η-βενζιμιδαζολο5-καρβονυλο)-πυριδιν-2-υλ-αμινο] προπιονικο αιθυλεστερα
PL370517A1 (en) Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h
TW200606144A (en) Crystal of 1,2-dihydropyridine compound
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
NO20064288L (no) Tetraazabenzo(E)azulen-derivater og angaloger derav
NO20054852L (no) GFAT inhibitorer
TW200716610A (en) Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
IL183700A0 (en) Process for production of (4,5-dihydroisoxazol-3-yl)thio-carboxamidine salts
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
GEP20104927B (en) Formulations of a src/abl inhibitor
TW200700416A (en) 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites
MX2009003974A (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion.
TW200833337A (en) Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline
AU2003235814A8 (en) Novel process for the preparation of trans-3- ethyl-2,5- dihydro-4- methyl-n-(2-( 4-(((((4-methyl cyclohexyl) amino)carbonyl) amino)sulfonyl) phenyl)ethyl) -2-oxo-1h-pyrrole -1-carboxamide
UA95601C2 (ru) Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1метил-1н- бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и фармацевтическая композиция, которая его содержит
SI1315723T1 (en) The hydrochloride salt of 5(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione
UA101816C2 (en) Polymorphic forms of n-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide
IL182445A0 (en) Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfona mido-dibenzo[b,d]furan-1-caboxamide
IL153280A0 (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4 dione hydriodide as pharmaceutical
WO2008005955A3 (en) Synthesis of heterocyclic compounds
PL373929A1 (pl) Sposób wytwarzania N-(5-amino-2-metylofenylo)-4-(3-pirydylo)-2-pirydynoaminy
AU2003232376A1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating anaplastic thyroid cancer
MX2007000892A (es) Un hidrato variable cristalino de la sal de (s)-3-piridincarboxami da, 6-[4-[2-[[3-(9h-carbazol-4-iloxi)-2-hidroxipropil]amino]-2-met ilpropil]fenoxi]-hemisuccinato.
WO2004099129A3 (en) Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same